TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Apr 28, 2021 12:33 JST
Source:
Eisai
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan
Building Dementia Ecosystem
TOKYO, Apr 28, 2021 - (JCN Newswire) - Saitama Resona Bank, Limited, a corporation of the Resona Group, and Eisai Co., Ltd. announced today that both parties have entered into a business alliance agreement for building an ecosystem with the aim of supporting people living with and preventing dementia ("dementia ecosystem"), in order to realize a regional community where citizens of Saitama Prefecture can live with peace of mind for a long time while maintaining their health.
Image of a sustainable community with dementia ecosystem
In Saitama Prefecture, the speed of aging of society is estimated to be at the top level in Japan. Therefore, one of the major issues is making efforts to create a community where people can live with dementia, and prevent the onset of dementia. Through this business alliance, Resona and Eisai will build a "dementia ecosystem" that combines Resona's customer network in Saitama Prefecture and Eisai's wealth of experience and knowledge in drug creation activities and disease awareness activities in the field of dementia, aiming to support Saitama citizens and people working in companies in Saitama prefecture to maintain a healthy life and create a sustainable community.
As the first step in this effort, the customers of the investment trust "SAITAMA RESONA GLOBAL BALANCE PLUS ESG - SaitamaDGs -"(1) handled by Resona will be provided with Eisai's digital tool for self-assessment of brain performance (brain health) "NouKNOWTM" (pronounced "NOH-NOH", non-medical device).(2) We will provide the customers at Resona with opportunities to build assets and contribute to the local community through investment in Saitama Prefecture bonds, etc., and support them to secure their life by providing an opportunity to regularly check brain performance and maintain brain health by improving lifestyle habits.
Furthermore, Resona and Eisai will collaborate with local governments, companies, universities, public institutions, etc. in Saitama Prefecture through the dementia ecosystem, aiming to co-create value for realizing a sustainable community where citizens of the prefecture can live with peace of mind. For example, to reduce and eliminate anxieties, to enable them to lead a prosperous retirement life, or to enable companies in Saitama Prefecture to engage in efforts for health and productivity management.
(1) This is an investment trust in which Resona makes international diversified investments and ESG investments as a medium- to long-term asset formation support for its customer, as well as investments in Saitama prefectural bonds. Resona provides its customers with the opportunity to participate in the realization of the SDGs and contribute to the local community and society in Saitama Prefecture through their asset management. Resona will meet the needs of its customers who want to contribute to the creation of a society that can withstand the COVID-19 pandemic, by donating a part of the profits of the product to Saitama Prefecture's "COVID-19 Infection Countermeasure Fund" which is the initiative taken by the Saitama Prefecture Office to support the activities of medical professionals and medical institutions.
(2) "NouKNOW" is conducted through a simple card test using a PC or tablet device to quantitatively measure brain performance in four tests evaluating psychomotor function, attention, learning and memory, and working memory. This digital tool allows users to self-assess independently and in a short time frame (approx.15 minutes), enabling regular assessments in instances such as daily life and health checkups. On the results screen, a score (brain performance index (BPI)) - as a measurement of quantified brain performance aspects such as memorization, cognition, and decision - appears along with lifestyle advice for maintaining brain performance.
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
July 17 2026 23:24 JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
July 15 2026 23:18 JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
July 15 2026 22:51 JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 15 2026 22:21 JST
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 13 2026 23:06 JST
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
July 02 2026 21:45 JST
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
July 02 2026 21:01 JST
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
June 17 2026 12:28 JST
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
More Press release >>
Latest Press Release
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Jul 18, 2026 00:24 JST
Hitachi and NVIDIA collaborate to advance HMAX and enable end-to-end autonomous operations through the integrated control of physical AI
Jul 17, 2026 23:35 JST
Toyota's First "BE creation" Spin-Off Begins Operations in Japan
Jul 17, 2026 23:00 JST
MHI Advances AI Infrastructure Commercialization with U.S. Deployment of 10MW-Class Chiller and MCP Development
Jul 17, 2026 22:47 JST
Noetra Launches Full-Scale R&D for Japan-Developed Multimodal Foundation Model
Jul 17, 2026 22:16 JST
Mitsubishi Motors Launches the Xforce HEV in Indonesia
Jul 17, 2026 21:47 JST
Fujitsu to explore physical AI development and implementation across industries with FANUC, Yaskawa Electric, and Kawasaki Heavy Industries integrating NVIDIA technology
Jul 17, 2026 21:05 JST
JCB Celebrates 30 Years of Trust, Honoring 70 Years of Japan-Philippines Friendship
Jul 17, 2026 10:00 JST
TANAKA Commences Operation of "TANAKA H2 Nexus", One of Japan's Largest 500 kW Pure Hydrogen Fuel Cell Power Generation Facilities
Jul 16, 2026 22:00 JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Jul 16, 2026 00:18 JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 23:51 JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 15, 2026 23:21 JST
NEC develops world's first proprietary-AI technology to rapidly generate highly detailed 3D models solely from general-purpose camera footage while automatically removing unnecessary subjects
Jul 15, 2026 22:53 JST
Hitachi Rail achieves EcoVadis platinum medal, ranking among the top 1% of companies worldwide for sustainability performance
Jul 15, 2026 22:35 JST
Anime Tokyo Station Reaches 300,000 Visitors!
Jul 15, 2026 11:00 JST
Fujitsu launches AI-driven modernization service to accelerate legacy system transformation
Jul 14, 2026 19:12 JST
Anime Tokyo Station: TV Anime "BLEACH: THE BLOOD WARFARE - The Calamity" Special Exhibition
Jul 14, 2026 11:00 JST
JCB Signs Memorandum of Understanding with Circle to Explore Collaboration Utilizing Stablecoins
Jul 14, 2026 10:00 JST
Mitsubishi Power Receives Contract to Supply Boilers for Fuel Conversion Work at Existing Thermal Power Plants in Saudi Arabia
Jul 14, 2026 00:58 JST
Fujitsu developed an AI Agent to collaborate with store managers for AEON Food Style's strategic store operations
Jul 14, 2026 00:38 JST
More Latest Release >>